| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model
|
Trédan, Olivier
|
|
2014
|
10 |
2 |
p. 189-198
|
article
|
| 2 |
Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study
|
Li, Jiaping
|
|
2014
|
10 |
2 |
p. 287-295
|
article
|
| 3 |
Decreased mRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma
|
Peters, Inga
|
|
2014
|
10 |
2 |
p. 267-275
|
article
|
| 4 |
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)
|
Donini, M.
|
|
2014
|
10 |
2 |
p. 277-286
|
article
|
| 5 |
Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology
|
Dhillon, Sohita
|
|
2015
|
10 |
2 |
p. 303-310
|
article
|
| 6 |
Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports
|
Egron, Adeline
|
|
2014
|
10 |
2 |
p. 229-234
|
article
|
| 7 |
Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature
|
Ihnenfeld Arciénega, Isabel
|
|
2014
|
10 |
2 |
p. 297-301
|
article
|
| 8 |
Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC
|
Bosc, Cecile
|
|
2014
|
10 |
2 |
p. 247-253
|
article
|
| 9 |
Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists
|
Rey, Jean-Baptiste
|
|
2014
|
10 |
2 |
p. 199-213
|
article
|
| 10 |
Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis
|
Niess, Hanno
|
|
2014
|
10 |
2 |
p. 215-227
|
article
|
| 11 |
Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies
|
Tie, Jeanne
|
|
2014
|
10 |
2 |
p. 179-188
|
article
|
| 12 |
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
|
Smith, Donald L.
|
|
2014
|
10 |
2 |
p. 235-245
|
article
|
| 13 |
Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial
|
Heigener, David F.
|
|
2014
|
10 |
2 |
p. 255-265
|
article
|
Journal description